Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.52 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.36 |
| ▸ | FEN1 | P39748 | 2/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 8/20 | 0.34 |
| ▸ | IKBKB | O14920 | 3/20 | 0.34 |
| ▸ | CHUK | O15111 | 3/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3415657 | 0.84 | IKBKB (0.51) | ALOX5APFEN1IKBKBCHUKROCK1 | |
| SCHEMBL13266086 | 0.84 | MAP3K5 (0.34) | MAP3K5PTGDR2 | |
| SCHEMBL13241054 | 0.84 | PTGDR2 (0.36) | MAP3K5PTGDR2 | |
| SCHEMBL2981737 | 0.80 | TP53 (0.32) | PTGDR2 | |
| SCHEMBL2980033 | 0.79 | IKBKB (0.39) | MAP3K5IKBKBCHUK | |
| SCHEMBL2980032 | 0.79 | MMP1 (0.34) | MAP3K5IKBKBCHUK | |
| SCHEMBL2981793 | 0.78 | KMT2A (0.38) | IKBKBCHUK | |
| SCHEMBL2981796 | 0.78 | MMP1 (0.32) | — | |
| SCHEMBL2984751 | 0.74 | MAP3K5 (0.43) | MAP3K5CAPN1MCL1PTGDR2 | |
| SCHEMBL2985022 | 0.74 | MAP3K5 (0.73) | MAP3K5ALOX5APFEN1IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
| WO-2008145688-A2 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | NFKBIA, PACSIN2, MAP3K2 | MAP3K5 7/4885ALOX5AP 1502/4885FEN1 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.